News

The Phase II trial is being conducted under an investigational new drug (IND) application to the US Food and Drug Administration (FDA) and is the first to test

Oxycodone is used in the management of pain, especially in opioid tolerant patients. The company will introduce the product soon and will be amongst the few generic versions

Both the entities will jointly work to further develop the Etubics Platform, which is employed to develop new immunotherapeutic product candidates to treat cancer. As part of the

SMA is characterized by lower motor neuron loss and progressive muscle weakness and is caused by a genetic defect in the SMN1 gene that codes SMN, a protein

Progenics Pharmaceuticals has exclusively licensed development and commercialization rights for its first commercial product, Relistor, to Valeant. Relistor is a peripherally acting mu-opioid receptor antagonist designed to block

The trial is designed to evaluate the efficacy and safety of omadacycline compared with linezolid in ABSSSI. Omadacycline is the first in a new class of tetracyclines called

Selectins are a family of molecules, which are believed to play a major role in regulating cellular interactions within blood vessels. SCD is a rare and debilitating chronic

BIND is collaborating with AstraZeneca on the development of AZD2811, an Aurora B Kinase inhibitor that has been shown to be active in both solid and hematological tumors

Offering "Value through Innovation" as purveyors of prescription medication and consumer healthcare around the globe; Boehringer Ingelheim work in partnership with the world’s leading retailers to offer category